| Literature DB >> 23483084 |
Abstract
The objective here was to review the effects of polyvinylpyrrolidone (PVP) upon sperm function and embryonic development in humans. PVP has been used successfully in intracytoplasmic sperm injection (ICSI) to facilitate the handling and immobilization of sperm for both domestic animals and humans. In our previous reports, PVP solution exists locally in embryos injected during the early developmental period, and also exerts influence over the developmental capacity of such embryos. In other reports, PVP causes significant damage to sperm membranes that can be detected by transmission electron microscopy, and has been associated with chromosomal abnormalities in pregnancy derived from ICSI embryos. In some Japanese clinics, PVP-free media has been used for sperm immobilization in order to optimise safety. Consequently, it is strongly suggested that the success rate of fertilization and clinical pregnancy could be improved by using PVP-free solution for human ICSI. In conclusion, our interpretation of the available data is to perform ICSI without PVP or select a lower concentration of PVP solution in order to reduce safety for pregnancy and children born via ICSI.Entities:
Keywords: Clinical utility in vitro embryo production in human; Embryo development; Polyvinylpyrrolidone (PVP); Sperm capacitation
Year: 2012 PMID: 23483084 PMCID: PMC3588556 DOI: 10.1007/s12522-012-0126-9
Source DB: PubMed Journal: Reprod Med Biol ISSN: 1445-5781
The use of PVP in clinical reports for 20 years
| PVP used/not used | PVP brand | Fertilization rate | Cleavage rate | Clinical pregnancy rate | References |
|---|---|---|---|---|---|
| × | – | 80.0 | 80.0 | 0.0 | [ |
| o | – | 41.7 | 41.7 | 50.0 | [ |
| × | – | 68.0 | 52.9 | 14.3 | [ |
| × | – | 69.0 | 13.3 | 44.6 | [ |
| o | – | 66.7 | 75.0 | 50.0 | [ |
| o | – | 86.7 | 15.4 | 16.7 | [ |
| o | – | 73.9 | 22.4 | 40.9 | [ |
| o | – | – | – | – | [ |
| o | – | – | – | – | [ |
| o | – | – | – | – | [ |
| o | – | – | – | – | [ |
| × | – | – | – | – | [ |
| × | – | – | – | – | [ |
| o | – | – | – | – | [ |
| o | – | 82.6 | 69.5 | – | [ |
| o | ICN Biochemicals | – | – | – | [ |
| o | Scandinavian IVF Science AB | 64.3 | – | 28.4 | [ |
| o | Scandinavian IVF Science AB | 67.6 | 62.2 | 17.0 | [ |
| o | SAGE IVF Inc. | 66.7 | 54.4 | 46.8 | [ |
| o | VitroLife | 58.3 | 95.7 | 37.0 | [ |
| o | VitroLife | 73.0 | – | 31.3 | [ |
| o | VitroLife | 71.3 | 92.8 | 40.9 | [ |
| o | Fertipro | 59.3 | 55.8 | 46.3 | [ |
| o | Fertipro | 57.0 | 54.0 | 18.1 | [ |
| o | Sigma | – | – | – | [ |
| o | Sigma | 19.0 | 14.2 | 50.0 | [ |
| o | Sigma | 69.4 | 62.9 | 44.4 | [ |
| o | Sigma | – | 25.0 | 25.0 | [ |
| o | Sigma | – | – | – | [ |
| o | Sigma | 80.9 | 88.3 | 26.7 | [ |
| o | MediCult | 85.8 | – | 20.9 | [ |
| o | MediCult | 56.3 | – | 37.1 | [ |
| o | MediCult | 87.1 | – | 21.6 | [ |
| o | MediCult | 80.9 | 78.9 | 40.6 | [ |
| o | MediCult | 62.6 | 60.6 | 31.1 | [ |
| o | MediCult | 67.0 | 51.3 | 28.9 | [ |
| o | MediCult | 61.9 | – | 57.1 | [ |
| o | MediCult | 27.0 | 27.0 | 33.3 | [ |
| o | MediCult | 45.0 | – | – | [ |
| o | MediCult | 75.6 | 75.6 | 44.1 | [ |
| o | MediCult | 69.0 | 69.0 | 49.1 | [ |
| o | Irvine Scientific | 58.6 | 84.1 | – | [ |
| o | Irvine Scientific | – | – | – | [ |
| o | Irvine Scientific | 40.0 | 40.0 | 33.3 | [ |
| o | Irvine Scientific | 43.0 | 39.0 | – | [ |
| o | Irvine Scientific | 73.9 | 82.7 | 28.6 | [ |
| o | Irvine Scientific | 67.7 | 50.3 | 25.0 | [ |
| o | Irvine Scientific | 67.9 | – | 37.5 | [ |
| o | Irvine Scientific | – | 43.9 | 44.8 | [ |
| o | Irvine Scientific | – | – | – | [ |
aFertilized oocytes per injected metaphase II oocyte
bCleavaged oocytes per injected metaphase II oocyte
cThe number of pregnancy per embryo transferred
Figure 1Effect of PVP on capacitation and the acrosome reaction in bovine sperm. Uncapacitated bovine sperm suspension was incubated for 0, 15, 30 and 60 min in the absence (A) or presence (B) of 10 % PVP in modified‐SOF and then analysed using CTC stain. Experiments were repeated six times. Data represent the percentage of cells expressing the F pattern (open bars), B pattern (filled bars), and AR pattern (hatched bars) of CTC fluorescence. Values represent mean ± SEM. Annotation (a, b) indicates p < 0.05 compared to 0 min (ANOVA: F 6,38 = 0.0068). Asterisks indicate p < 0.05 compared to controls. n the number of sperm. Figure from Kato and Nagao [30]
In vitro developmental rate of bovine embryos to the blastocyst stage following intracytoplasmic injection with PVP solution (n = 3–9)
| Number of oocytes | Number of embryos cleaved (%) | Number of blastocysts (%) | |
|---|---|---|---|
| Injected product | |||
| None (control) | 129 | 105 (81.4 %)a | 31 (24.0 %)c |
| SOF | 79 | 62 (78.5 %)a | 19 (24.1 %)c |
| PVP | 73 | 38 (52.1 %)b | 5 (6.8 %)d |
| Brand of PVP injected | |||
| Sigma | 90 | 44 (48.9 %)e | 13 (14.4 %)gh |
| Irvine | 115 | 79 (68.7 %)e | 24 (20.9 %)g |
| Fertipro | 110 | 53 (48.2 %)f | 9 (8.2 %)h |
| Injection medium | |||
| 199 | 65 | 41 (63.1 %) | 9 (13.8 %) |
| SOF | 95 | 63 (66.3 %) | 11 (11.5 %) |
| HTF | 61 | 36 (59.0 %) | 6 (9.8 %) |
This table was from Kato and Nagao [30]
n number of replicated experiments, letters within columns indicate significant differences (a–b χ 2 = 10.142, p < 0.001, c–d χ 2 = 10.14, p < 0.01, e–f χ 2 = 12.09, p < 0.01, g–h χ 2 = 7.260, p < 0.05)
PVP availability reported during the past 20 years
| Use/or not PVP | PVP brand | Fertilization rate | Cleavage rate | Pregnancy rate |
|---|---|---|---|---|
| ○ | Scandinavian IVF Science AB ( | 66.0 | 62.2 | 22.7 |
| ○ | SAGE IVF Inc. ( | 66.7 | 54.4 | 46.8 |
| ○ | VitroLife, Kungsbacka, Sweden ( | 67.5 | 94.3 | 36.4 |
| ○ | Fertipro, Belgium ( | 58.2 | 54.9 | 32.2 |
| ○ | Sigma, St. Louis, MO, USA ( | 56.4 | 47.6 | 36.5 |
| ○ | MediCult, Jyllinge, Denmark ( | 65.3 | 60.4 | 36.4 |
| ○ | Irvine Scientific, Santa Ana, Ca, USA ( | 58.5 | 56.7 | 33.8 |
aThe average of fertilization rates in the reports (n)
bThe average of cleavage rates in the reports (n)
cThe average of pregnancy rates in the reports (n)
Composition of injection media for human intracytoplasmic injection of PVP
| Fertipro | MediCult | SAGE IVF Inc (present; CooperSurgical, Inc.) | Irvine Scientific | VitroLife |
|---|---|---|---|---|
| Water | Water | Water | Water | Water |
| Sodium chloride | – | Sodium chloride | Sodium chloride | Sodium chloride |
| Potassium chloride | – | Potassium chloride | Potassium chloride | Potassium chloride |
| Calcium chloride | – | Calcium chloride | Calcium chloride, anhydrous | Calcium chloride |
| Sodium dihydrogen phosphate | – | – | – | – |
| – | – | Potassium phosphate, anhydrous | Potassium phosphate, monobasic | Potassium di‐hydrogen |
| Magnesium sulfate | – | Magnesium sulfate | Magnesium sulfate, anhydrous | Magnesium sulfate |
| Sodium pyruvate | Sodium pyruvate | Sodium pyruvate | Sodium pyruvate | Sodium pyruvate |
| Glucose monohydrate | Glucose | Glucose | Glucose | Glucose |
| Sodium lactate | – | Sodium lactate | Sodium lactate | Sodium lactate |
| Sodium bicarbonate | Sodium bicarbonate | Sodium bicarbonate | Sodium bicarbonate | Sodium bicarbonate |
| Taurine | ||||
| Alanyl‐glutamine | ||||
| HEPES | Hepes free acid | HEPES | – | – |
| – | Hepes sodium salt | – | – | – |
| – | – | EDTA | – | EDTA |
| Human serum albumin | Human serum albumin | Human serum albumin 5 mg/mL | Human serum albumin 7–10 % | Recombinant human albumin |
| Polyvinylpyrrolidone | Polyvinylpyrrolidone | Polyvinylpyrrolidone | Polyvinylpyrrolidone | Polyvinylpyrrolidone |
| – | Streptomycine sulfate salt | Gentamicin | Gentamicin | – |
| – | Penicillin sodium salt | – | – | – |
| – | Phenol red (not product no. 1090) | Phenol red | – | – |
| – | EBSS | – | – | |
| Synthetic Serum Replacement (SSR®; USA: ART supplement contains recombinant human insulin) | – | – | – |
Figure 2The location of PVP solution in embryos. a PVP was generally not observed in the embryo and appeared similar to the control. b PVP generally dispersed with some PVP remaining at the injection site. c Entire volume of PVP remaining in parts of the oocyte. Arrows show the localization of PVP solution. Figure from Kato and Nagao [30]
The risk of PVP and HA during ICSI treatments
| Report A [ | Report B [ | Report C [ | Report D [ | |||||
|---|---|---|---|---|---|---|---|---|
| Group HA | Group PVP | Group HA | Group PVP | Group HA | Group PVP | Group HA | Group PVP | |
| Number of cycles | 58 | 65 | 48 | 44 | 125 | 107 | ||
| Fertilization rate | 72.6 % (525/723) | 74.6 % (484/649) | 72 % (360/499) | 75 % (337/449) | 91.6 % (304/332) | 85.8 % (236/275) | 93.4 % (874/936) | 87.1 % (223/256) |
| Clinical pregnancy rate | 50 % (29/58) | 38.5 % (25/65) | 41.7 % (20/48 ) | 43.2 % (19/44) | 24.8 % (31/125) | 20.9 % (22/105) | 32.8 % (107/326) | 21.6 % (21/96) |
| Implantation rate | 18.6 % (41/221) | 14.0 % (35/250) | 18.1 % (27/149) | 19.1 % (27/141) | 12.4 % (35/282) | 10.2 % (23/226) | 17.1 % (133/778) | 10.3 % (22/213) |
aFertilized oocytes per injected metaphase II cumulus–oocytecomplex
bThe number of pregnancy per embryo transferred
cTnumber of gestation sacs per embryo transferred